Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
M-Star Therapeutics
South San Francisco, California, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Star Therapeutics is a late clinical-stage biotechnology company developing best-in-class monoclonal antibodies for bleeding disorders and other diseases. Its lead program VGA039, a monoclonal antibody targeting Protein S, has completed Phase 1 studies (VIVID 1 in healthy volunteers and VIVID 2 in von Willebrand disease patients) with positive interim data and has advanced into VIVID 6, a pivotal Phase 3 global trial in patients with all types of von Willebrand disease.[3][4][5]
- Therapeutic areas
- Hematology
- Modalities
- Monoclonal antibodyAntibodyBiologic
- Industry
- Biotech
02
Partnerships
Sanofi Ventures
Beyond the preview
Go deeper on M-Star Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M-Star Therapeutics.